Affimed (NASDAQ:AFMD) Price Target Lowered to $4.00 at Stifel Nicolaus

Affimed (NASDAQ:AFMD) had its target price lowered by analysts at Stifel Nicolaus from $5.00 to $4.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 9.59% from the company’s previous close.

AFMD has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Affimed in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Affimed Stock Down 2.7 %

Shares of AFMD opened at $3.65 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 52 week low of $2.92 and a 52 week high of $8.95. The stock has a fifty day moving average of $3.50 and a 200-day moving average of $4.54.

Affimed (NASDAQ:AFMD) last posted its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. As a group, research analysts forecast that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Choreo LLC bought a new stake in Affimed in the second quarter worth approximately $54,000. FMR LLC boosted its holdings in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares in the last quarter. Finally, Intellectus Partners LLC grew its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.